Diffusion-weighted MRI as a biomarker for treatment response in glioma

Kathleen M Schmainda*

SUMMARY  Diffusion-weighted imaging (DWI) is a powerful MRI method, which probes abnormalities of tissue structure by detecting microscopic changes in water mobility at a cellular level beyond what is available with other imaging techniques. Accordingly, DWI has the potential to identify pathology before gross anatomic changes are evident on standard anatomical brain images. These features of tissue characterization and earlier detection are what make DWI particularly appealing for the evaluation of gliomas and the newer therapies where standard anatomical imaging is proving insufficient. This article focuses on the basic principles and applications of DWI, and its derived parameter, the apparent diffusion coefficient, for the purposes of diagnosis and evaluation of glioma, especially in the context of monitoring response to therapy.
Traditionally, brain tumor response to treatment has been assessed using the MacDonald criterion [1], which is based on the two-dimensional measurement of enhancing tumor on MRI or computed tomography. Given that tumor enhancement primarily reflects the breakdown of the blood–brain barrier (BBB), it may not reflect true changes in tumor growth. For example, for patients on the Stupp protocol, ‘pseudoprogression’ can occur where there is an increase in tumor enhancement on MRI suggestive of tumor progression, but without increased tumor activity [2]. Pseudoprogression is confirmed later by a stabilization or decrease in tumor enhancement on imaging or with tissue obtained at surgery. An imaging biomarker capable of distinguishing these effects early on would be of tremendous benefit for these patients. Similarly, radiation necrosis, occurring 3–12 months after radiotherapy, can mimic tumor recurrence with increased enhancement, raising similar treatment questions.

For similar reasons use of the MacDonald criteria [3] or, more recently, the RANO criteria [4], which also incorporates fluid-attenuated inversion recovery imaging (FLAIR), may be insufficient for the full evaluation of response to antiangiogenic therapies, such as bevacizumab [5]. Since these agents also act as powerful steroids, decreasing the permeability of the BBB, rapid decreases in the degree of contrast enhancement and extent of surrounding hyperintense T2-weighted signal intensity on FLAIR images may not reflect true changes in tumor activity. This phenomenon, termed ‘pseudoresponse’ [2], may explain why an improvement in progression-free-survival, but not overall survival, has been observed for patients treated with these agents, in that standard imaging is not an accurate representation of both enhancing and nonenhancing tumor growth. Related to this, there is evidence from both preclinical [6–8] and recent clinical studies [9,10] concerning a possible relationship between antiangiogenic drugs and increased tumor cell invasion. Clearly there is a need for imaging biomarkers that provide objective information related to tumor growth and invasion.

Diffusion-weighted imaging (DWI) has the potential to serve as an imaging biomarker for these purposes, since it can provide objective information about tissue and tumor cell density, and thus cell death and tumor cell invasion. Therefore, the focus of this review will be on DWI and its derived parameters, the most important of which is apparent diffusion coefficient (ADC), and its utility as an imaging biomarker in glioma. Specifically, this review will include a brief review of the basic principles of DWI followed by a description of the relationship between ADC and cell density, the potential of ADC and related parameters to distinguish tumor types and grades, and their ability to provide important information regarding response to treatment.

**Basic principles of DWI**

In MRI, the unique spatial information necessary to produce images is generated through the application of imaging gradients, which are magnetic fields that vary with position. MRI is made sensitive to tissue water diffusion by adding additional imaging gradients, called diffusion gradients, which are much larger than the standard imaging gradients. More specifically, as shown in Figure 1, the images are made sensitive to diffusion by adding two identical magnetic field gradients, one on each side of the 180° ‘refocusing’ radiofrequency pulse. These two gradients, separated in time, are effectively the inverse of each other due to the 180° pulse applied between. Water ‘spins’ accumulate spatially dependent phase during the first gradient pulse. The second gradient pulse reverses the phase introduced by the first gradient pulse. Any translation of the spins (i.e., diffusion), during and between the two gradients, results in a phase offset proportional to the distance traveled. This results in an attenuation of the measured diffusion-weighted signal as defined by the following equation:

\[
S(b) = S_0 e^{-b ADC} e^{-\gamma \delta G/2}
\]

where ADC is given in units of mm²/s, TE is the echo time, T2 is the tissue transverse relaxation time and b is the diffusion weighting or ‘b-value’. Note that since the diffusing water is not freely diffusing but instead is restricted by many different barriers, such as cell membranes, the measured diffusion coefficient is referred to as the ADC rather than simply D, the diffusion coefficient. The b-value is a function of the magnetic resonance frequency for the nuclei (γ; which in this case is water), diffusion gradient strength (G), diffusion gradient duration (δ), and diffusion gradient separation (Δ). For the DWI sequence shown in Figure 1 the equation...
describing the b-value is:

\[ b = (y|G|\delta)[\Delta - \frac{\delta}{3}] \]  

Equation 2

From Equation 1 it is clear that when either ADC or the b-value increases, the signal decreases. Conversely, if the ADC decreases, as can occur with a more restricted tissue environment, the DWI signal will increase. However, changes in tissue T2 that might occur, for example, with edema, also influence the DWI signal resulting in what is termed a ‘T2-shine-through’ effect. Consequently, to determine changes in ADC alone, the DWI signal is measured at a minimum of two different b-values and ADC computed.

\[ ADC = \frac{1}{(b1 - b2)} \ln\left(\frac{S0}{S1}\right) \]  

Equation 3

In the brain, the b-values that are most commonly used for determination of ADC are \( b = 0 \) and \( b = 1000 \text{ s/mm}^2 \). These values were chosen to maximize the signal to noise of the computed ADC image map. However, more recent recommendations suggest that the minimum b-value be a nonzero value. Choosing b-values of the order of 50–200 s/mm² will minimize contributions from fast diffusing components that may result from microvascular perfusion rather than true tissue water diffusion. These intravoxel incoherent motion effects have been well studied in the brain in the past [11,12], and are being addressed again in several more recent studies [13].

It should be noted that DWI maps are generated from the average of three diffusion-weighted signals, each obtained by applying the diffusion gradients in three orthogonal directions. This results in the voxel-wise display of an isotropic diffusion-weighted signal, which by definition is independent of direction. A related technique called diffusion tensor imaging (DTI) enables the calculation of both the direction and magnitude of the water diffusion. This technique is designed to probe the directional differences of diffusion in the brain’s gross microstructure, such as in white matter tracts. DTI requires the acquisition of at least six DWI each with different diffusion gradient directions, but a common diffusion time that is long enough to allow a residing proton to probe the microstructure for the purpose of obtaining the diffusion tensor matrix [14]. DTI has primarily played a role in the presurgical mapping of brain tumors in an effort to avoid damage to these tracts [15–17]. There have also been studies demonstrating that fractional anisotropy, a parameter that is derived from DTI data, may provide information about tumor invasion into white matter tracts [18,19]. However, DTI is beyond the scope of the present review, and therefore this review will continue to focus on DWI and its applications for evaluating glioma.

**Figure 1. A diffusion-weighted imaging sequence.** Shown are the typical timing of events that occur with a diffusion-weighted imaging sequence. They include application of radiofrequency (r.f.) pulses, consisting of a 90 and 180 (inversion) pulses, and diffusion gradients (g). The sequence of signals generated are also shown. Not shown are the imaging gradients, which are required for the measurement of spatially localized magnetic resonance signals. The diffusion weighting or b-value is defined by the diffusion gradient duration (\( \delta \)), its amplitude (G), and the time between application of the identical diffusion gradients (\( \Delta \)).

\( \delta \): Diffusion gradient duration; g: Diffusion gradients; G: Amplitude; r.f.: Radiofrequency.

**DWI for brain tumors**

DWI is a rather recent addition to the magnetic resonance sequences conventionally employed to diagnose and follow brain tumors. Early on DWI was used most frequently in the evaluation of stroke. Within seconds of stroke onset, cytotoxic edema occurs, where there is a shift of water from the extracellular to cellular space, resulting in a greater restriction of water movement. This restriction is visible as increased signal on DWI (Equation 1). Likewise for densely cellular neoplasms, which have a greater restriction of water diffusion compared with less cellular tissues, this gives rise to increased signal on DWI and decreased ADC. The relationship between ADC and tumor cellularity has been demonstrated in several studies [20–22]. The results from one such study [22] are shown in Figure 2 where cell density, measured via histological analysis, was compared with the ADC values computed in the corresponding location.
In this context, additional studies demonstrated that the ADC correlated inversely with tumor proliferation rates as measured by the Ki-67 labeling index [23], and was predictive of...
prognosis in a manner independent of tumor grade [24]. Note that the tumor classification and grading labels used throughout this review are based on those defined by WHO in their 1993 classification [25]. With respect to astrocytoma/glioma, a four-tiered system is applied, where low-grade tumors refer to both grade I and II tumors, and high-grade tumors refer to those diagnosed as grade III or grade IV tumors. The validity of these relationships was further supported by yet another study showing that the diagnosis of early stages of malignant glioma can be aided with DWI, such that areas of low ADC, suggestive of high cellularity, are more consistent with high-grade glioma [26]. As an example, Figure 3 shows DWI and ADC maps for two patients, one with a grade II and another with a glioblastoma (grade IV glioma). For the grade II tumor, the enhancing tumor, indicated by the arrow, corresponds to an area of high signal on both DWI and ADC maps, consistent with a tumor that may be hypocellular compared with normal-appearing brain. Conversely, areas of enhancing glioblastoma correspond to areas of low ADC, suggesting a more densely cellular tumor.

Despite these promising results, other investigators have questioned the relationship between ADC and tumor cell density, and have highlighted the considerable overlap between low- and high-grade gliomas. It was suggested that this overlap may be attributed to the focal necroses commonly found in grade IV gliomas, which causes the overall ADC values to be higher [27,28].

Figure 3. Diffusion-weighted images and apparent diffusion coefficient images for low- and high-grade glioma. Shown are postcontrast T1-weighted images (A & D), diffusion-weighted images obtained at $b = 1000 \text{ s/mm}^2$ (B & E) and the corresponding apparent diffusion coefficient maps (C & F) for patients with grade II astrocytoma (A–C) and recurrent glioblastoma (D–F), respectively. The bright signal on diffusion-weighted images can result from some combination of restricted diffusion and T2 hyperintensity, the latter of which can occur within edematous tissue, for example. The apparent diffusion coefficient maps eliminate T2 contributions so that restricted diffusion, shown as areas of darker image intensity, can be more clearly delineated. In turn, restricted diffusion may represent areas of increased tumor cell density.
This observation also raises the issue of using mean ADC values to grade gliomas, and underscores the need for new analysis methods that do not characterize the entire, often very heterogeneous tumor, by one averaged value for a region of interest. In addition, the relationship between ADC and tumor cell density in treated tumor, for which treatment effects may confound the relationship, requires further evaluation.

Finally, since diagnosis and tumor grade are established by histopathologic evaluation of tumor biopsy samples or surgical resection, an accurate diagnosis is very dependent on the accurate spatial sampling of the most aggressive parts of the tumor. In this context, information derived from diffusion imaging could be used to better guide such sampling with the potential for greater accuracy in sampling and diagnosis [29]. Thus, more accurate preoperative grading of primary brain tumors could increase the diagnostic yield of brain biopsies, thereby improving patient management.

**DWI metrics for the evaluation of treatment response**

As previously stated, conventional imaging is often not able to provide an early indication of the effectiveness of radiation therapy, chemotherapy and/or targeted therapies. Clearly biomarkers that can provide more specific information about tumor biology within both contrast-enhancing and nonenhancing areas are needed. Diffusion MRI has this potential, examples of which are described next.

- **Apparent diffusion coefficient**

Consistent with the idea that ADC inversely correlates with tumor cell density, several studies have demonstrated that a decrease in cellularity, and thus increase in ADC, is observed with successful treatment [30,31]. Likewise, DW-MRI was used to evaluate the effectiveness of the radiosensitizer gemcitabine in a mouse glioma model [32], where it was demonstrated that tumor diffusion values increased prior to detectable changes in tumor volume following treatment. Yet another study demonstrated that areas of restricted diffusion in patients with glioblastoma predicted sites that later enhanced, regardless of antiangiogenic therapy with bevacizumab [33]. More recently, a histogram analysis of ADC values was used to stratify progression-free and overall survival in patients with recurrent glioblastoma treated with bevacizumab in a multicenter study. Consequently, ADC alone has a demonstrated promise to predict both treatment response and failure. The potential is further demonstrated when ADCs collected over time are used to create functional diffusion maps (fDMs), the principles of which are described next, followed by examples demonstrating its potential as a biomarker to predict treatment response.

![Figure 4. Calculation of functional diffusion maps from sequential apparent diffusion coefficient maps.](image)

For each postbaseline time point, ADC maps from the current day are subtracted from baseline ADC maps. Each voxel within an ADC difference image is stratified into three categories based on the magnitude of the ADC change: a decrease in ADC suggestive of increased cellularity (blue voxels); an increase in ADC suggestive of decreased cellularity (red voxels); and those with no significant change in ADC (green voxels). ADC: Apparent diffusion coefficient; fDM: Functional diffusion map.

Reproduced from [22], with kind permission from John Wiley and Sons (License No. 2901470746078).
Functional diffusion maps

First developed by Moffat et al. [34–36], fDMs display changes in ADC that occur over time, and have demonstrated great promise as a new therapeutic biomarker for glioma. The creation of fDMs first requires image registration between a current ADC map and the baseline ADC map. After proper registration is verified, voxel-by-voxel subtraction is performed between ADC maps acquired at subsequent time points and the baseline, postsurgical, pretreatment ADC maps to create ∆ADC images. Individual voxels are then stratified into three categories based on the change in ADC relative to baseline ADC maps. Red voxels represent areas where ADC increased beyond the ∆ADC threshold (i.e., ‘hypocellular’ voxels), blue voxels represent areas within the tumor where ADC decreased beyond the ∆ADC threshold or confidence limits (i.e., ‘hypercellular’ voxels), and green voxels represent no change in ADC above or below the ∆ADC threshold. This process is summarized in Figure 4. Note that the terms ‘hypocellularity’ and ‘hypercellularity’ are used instead of increasing and decreasing ADC for ease of reference, but are given in quotation marks since there exist many tissue conditions other than cell density, such as edema, gliosis, infection and ischemia, that can contribute to such changes. These must all be considered in the context of a given case before concluding that true changes in cell density have occurred.

Early on, the fDM analysis was applied to ADC image voxels within the contrast-enhancing tumor only [34–36], and a graphical method was developed to show the portion of voxels within each category. An example of this graphical representation is shown in Figure 5. In these studies it was demonstrated that the volume of voxels with increasing ADC (i.e., red voxels) or the total volume of voxels with both increasing and decreasing values (red plus blue voxels) were predictive of response to chemotherapy.

Further validation of the fDM technique was carried out in a study by Ellingson et al. [22]. In this study, a comprehensive evaluation of the thresholds used to create the fDM categories was performed. Here it was demonstrated that the 95% confidence limits to categorize tissue as having no change in diffusion depend on whether the change is defined as relative to the range of values of white matter alone, gray matter, cerebrospinal fluid or a mixture of some or all tissues. Not surprisingly, the sensitivity and specificity to detect disease progression will change with the chosen ‘normal’ confidence limits. Still, with each limit chosen the distinction was always better than chance. In practice, a threshold of ±0.40 × 10⁻³ mm²/s is used, based on the 95% confidence limit of normal appearing white and gray matter. This choice is based on the results of the receiver operating characteristic analysis, confirming that this threshold gave the best sensitivity and specificity for distinguishing stable from progressive disease. Finally,
this validation study also led to the development of graded fDMs [37], which enables one to simultaneously view the fDM results using several different thresholds, each with a slightly different accuracy as defined by the validation study [22].

### Using ADC & fDM to evaluate response to cytotoxic & antiangiogenic therapies

To further explore the potential of fDM to predict response to therapy, Ellingson et al. [38] evaluated fDMs in glioma patients undergoing either cytotoxic or antiangiogenic therapies. In contrast to many previous fDM studies, that focused on changes in diffusion within contrast-agent enhancing tumor [34,35], the focus of this study was on changes in diffusion within abnormalities apparent on FLAIR images. These abnormalities, which are evident as bright areas compared with the surrounding normal-appearing brain, typically consist of enhancing tumor and a region much beyond that. In glioma, the FLAIR image abnormalities have been shown to represent some mixture of edema and invading tumor cells [39].

The results from this study, performed in a total of 50 patients with confirmed glioma, demonstrated that the rate of change in fDM ‘hypercellular’ volumes within FLAIR abnormalities, predicted tumor progression, time to progression and overall survival for both antiangiogenic and cytotoxic treatments earlier than standard anatomical imaging. Two examples of this are shown in Figures 6 & 7 for patients undergoing antiangiogenic and cytotoxic therapy, respectively. In each case the increase in the volume of blue ‘hypercellular’ voxels preceded changes observed on standard anatomical imaging. Thus, functional diffusion mapping, applied to both enhancing and nonenhancing tumors, clearly has the potential to serve as an imaging biomarker to track treatment response in glioma.

### Current issues & future considerations

As advanced imaging technologies, such as DWI, are being used more routinely to monitor therapies new demands regarding consistency of measurements over time and image registration requirements are arising. First, because of differences regarding how different vendors collect and process their DWI and thus ADC data, it is becoming increasingly difficult to accurately compare ADC across time when the data is obtained on different platforms for the same patient. In this regard, many have attempted or proposed homogenization of data collection and processing. However, this is always a ‘moving target’ given continual technology improvements, upgrades and simple issues of intellectual property and institutional preference. Instead it might be most reasonable to determine a way to

---

**Figure 6.** Standard MRI and functional diffusion maps in a patient with progressive disease after treatment with bevacizumab. A 47-year-old male with a history of glioblastoma multiforme completed radiotherapy with concurrent temozolomide, followed by adjuvant temozolomide. His tumor recurred radiographically just prior to baseline ADC maps. The patient was then changed to bevacizumab monotherapy, and initially contrast enhancement and FLAIR signal abnormality improved substantially. The patient declined neurologically over 4 months of bevacizumab treatment, despite a positive radiographic response on postcontrast T1-weighted (top row) and FLAIR images (middle row). The patient expired 2 months from the last fDM time-point (6 months after start of bevacizumab treatment). During bevacizumab treatment, fDMs showed a rapid increase in the volume of hypercellularity (blue voxels), indicative of failed treatment.


Reproduced from [43], with kind permission from Springer (License No. 2898871275280).
standardize the images as part of the postprocessing workflow, as has been previously proposed for postcontrast and perfusion imaging [40–42]. Or, more simply, and potentially more practically, each institution could implement the requirement to have each patient consistently scanned on the same platform over time. While this will not solve the problems that may occur with technology upgrades, for the most part it will ameliorate the majority of the inconsistencies that one would otherwise encounter.

Registration of diffusion images over time is also required for longitudinal assessment. In this regard, a wealth of image registration algorithms exist and have been applied. Typically, the higher resolution images are directly registered across time points. Then, assuming no motion occurred between the collection of the high-resolution image and the DWI data, for a given scanning session, the registration transformation is applied to the DWI and ADC data. This in general has been successful for registering DWI and ADC data over time, if the underlying DWI data is sufficiently similar as just discussed.

Additional issues of characterizing and optimizing the diffusion signal and the information that can be derived also need to be addressed. For example, while the focus of this paper was on DWI signal, which is typically obtained at two different b-values, there are studies to suggest that many more b-values, especially of higher value, can be of use. For example, if multiple b-values are collected that are sufficiently high, a sub-voxel diffusion heterogeneity index, termed ‘α’ can be determined [43]. This parameter may be a very early marker of tumor cell invasion due to its sensitivity to the breakdown of the extracellular matrix. Early results obtained in animals [43] and patients [44] support the potential of this approach. A similar approach, termed diffusion-kurtosis model, has also been developed with promise for evaluating gliomas [45,46]. Alternatively, an analytical solution to a glioma growth model was developed. This model allows for direct spatial quantification of microscopic tumor proliferation and migration based on serial diffusion MRI scans [47]. Although this approach appears promising, issues that affect accuracy, such as time interval between diffusion scans and noise levels, require further characterization.

As MRI technology continues to improve, new opportunities regarding how we measure the diffusion signal arise, which have important implications for how best to characterize tissue. For example, referring to Equation 2, the generation of diffusion weighting or b-value depends on many different gradient timing parameters. These, in turn, will dictate what
ranges of water diffusion, and thus what types and sizes of cellular components, we are sensitive to. Consequently, by setting these timings differently, new and different information about the pathology can be derived, as demonstrated early on in animal models [48]. These possibilities must always be taken into consideration as we strive to move the field of DWI and evaluation of gliomas forward.

Finally, despite much promise, before DWI and its derived parameters can be used routinely to distinguish progression from treatment response and thus make treatment decisions, it is imperative that rigorous pathological validation be carried out. While initial studies, referred to earlier, demonstrate a strong correlation between tumor cell density and ADC (Figure 2) [22], these studies were performed in untreated patients. It is therefore necessary to perform similar studies in treated patients where spatially accurate correlations between imaging and tissue parameters can be assessed. Of note, such studies are currently underway [49,50].

Conclusion & future perspective

In general, it is becoming well known that conventional radiologic imaging tends to significantly underestimate the extent of diffuse infiltrative glioma growth [51], and as such is proving insufficient for the complete evaluation of treatment response in glioma. Given the sensitivity of DWI and its derived parameters to tissue microstructure and cell density, it clearly has the potential to provide important biomarkers for treatment response in glioma. This was demonstrated by studies showing the ability of ADC to distinguish tumor grade, predict sites of recurrence and, with new methods such as fDM, for monitoring changes in ADC over time, may provide an even earlier and more accurate predictor of response. Specifically, according to the NIH, a biomarker is defined as ‘a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic responses to a therapeutic intervention’. Thus, DWI-derived parameters clearly fit this criterion.

Some technical and physiologic issues still need to be addressed. These include ensuring the consistency of data quality and information over time for a given patient, optimization of DWI parameters to most appropriately probe tissue structure, and further exploration and validation of both current and new analysis models.

Despite the necessity for further research and validation in multicenter settings, we suggest that it is already quite clear that DWI and its derived parameter ADC are playing, and will continue to play, an important role in the evaluation of treatment response in glioma.

Financial & competing interests disclosure

Funding support was provided through NIH/NCI CA082500, Advancing a Healthier Wisconsin Partnership Program. K Schmainda has ownership interest in Imaging Biometrics LLC. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

Papers of special note have been highlighted as:

- of interest
- of considerable interest


- Presents a nice overview of the current limitations with standard anatomical imaging methods for the assessment of treatment response.


10 Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology...
Diffusion-weighted MRI as a biomarker for treatment response in glioma

- Presents comprehensive studies to characterize the thresholds used for the creation of functional diffusion maps (fDMs).

- **Describes one of the seminal studies demonstrating the utility of changes in diffusion MRI measurements to monitor treatment response in brain tumors.**

- Extends fDMs to a multithreshold technique, which may prove to be more informative.

- The ability of fDMs to predict response to both chemotherapy and targeted therapies is demonstrated in this paper.


- Bedeker D, Jensen TR, Schmainda KM. Standardization of relative cerebral blood volume (rCBV) image maps for ease of both}

73, 1200–1206 (2009).


One of the first demonstrations of a new diffusion-weighted imaging-derived metric, termed $\alpha$-diffusion, with the potential to detect invading tumor based on sub-voxel heterogeneity.


Illustrates how diffusion imaging sequences can be designed to be more or less sensitive to certain tissue compartments.


Describes a way to precisely validate diffusion metrics with tissue analysis, where the tissue and images correspond spatially.